Dr. Bernhard Noreisch, LL.M.

Dr. Bernhard Noreisch LL.M.
Lawyer, Partner
  • Specialist in Commercial and Corporate Law
Department: Corporate Law Venture Capital / M&A
Location: Munich
T +49 89 544147-29
Download vCard

Expertise

Reputation

  • LEGAL 500 Germany 2020: recommended lawyer
  • JUVE handbook 2019|2020: leading lawyer in venture capital, often recommended lawyer (venture capital)
  • LEGAL 500 Germany 2019: recommended lawyer
  • JUVE handbook 2018|2019: leading name in venture capital, often recommended lawyer (venture capital)
  • LEGAL 500 Germany 2018: recommended lawyer ("outstanding" leader of the venture capital practice group)
  • JUVE handbook 2017|2018: leading name in venture capital, frequently recommended lawyer
  • The Legal 500 Germany 2017: recommended lawyer
  • JUVE handbook 2016|2017: leading name in venture capital, frequently recommended lawyer PE/VC (“very carefully”, competitor)
  • The Legal 500 Germany 2016: recommended lawyer („convinces with his calmness, competence and focus on solutions”)
  • JUVE handbook 2015|2016: frequently recommended lawyer PE/VC (“very good while at the same time very down-to-earth”, competitor)
  • JUVE handbook 2013|2014: frequently recommended lawyer
  • JUVE handbook 2013|2014: “brilliant corporate lawyer” (Competitor)
  • JUVE handbook 2011|2012: “a prudent, thoughtful and pleasant lawyer to be contacted” (Competitor)
  • JUVE handbook 2011|2012: “very pragmatic and individual legal advice” (Client)

Career

  • Studied law in Passau and Bayreuth
  • Additional studies in Economics in Bayreuth
  • Masters studies at the University of Edinburgh
  • Obtained law doctorate in Bayreuth
  • Admitted to the bar in 2003
  • Joined LUTZ | ABEL in 2003
  • Since 2007 specialist in Commercial and Corporate Law
  • 2011–2012 lecturer in Private Business Law at the University of Applied Sciences Munich
  • Specialist publications and lectures on Commercial and Corporate Law

Memberships

One of the 20 leading lawyers in venture capital in Germany.

JUVE handbook 2019|2020

News

  • LUTZ | ABEL advises in EUR 17 Million Series B round of financing for Temedica

    LUTZ | ABEL advises in EUR 17 Million Series B round of financing for Temedica

    Dr. Bernhard Noreisch, LL.M. Dr. Lorenz Jellinghaus Claudia Knuth Andreas Kössel Jan-Phillip Kunz, LL.M. Nina Sophie Osten Dr. Cornelius Renner Ute Schenn Dr. André Schmidt
    The healthcare start-up Temedica GmbH from Germany announced to have completed a € 17 million Series B financing round.
    recommend
    more
    close

    The financing round was led by different MIG-Fonds, Santo Venture Capital, G+J Digital Ventures, Salvia and Bernd Wendeln as investors. LUTZ | ABEL advised on the transaction.

    The German healthcare start-up Temedica GmbH, which is based in Munich and was founded by Gloria Seibert and Clemens Kofler, closed a € 17 million Series B financing round. MIG-Fonds, Santo Venture Capital and Salvia lead the round – existing shareholders like G+J Digital Ventures and Bernd Wendeln were additional investors.

    Founded in 2016, the start-up develops digital companions (such as apps) to support patients in their healing process and to improve their medical care. Until today Temedica came up with the products pelvina (to strengthen the pelvic base), Mineo (to strengthen the back) as well as Waya (for a healthy nutrition and motion sequence). Further product developments are in the process of planning.

    The LUTZ | ABEL team included the following attorneys: The partners Dr. Bernhard Noreisch (Munich) and Dr. Lorenz Jellinghaus (Hamburg) led the transaction. The team further consisted of Claudia Knuth (Labour Law, Hamburg), Andreas Kössel (Labour Law, Munich), Jan-Phillip Kunz (VC, Munich), Nina Sophie Osten (VC, Hamburg), Dr. Cornelius Renner (IT, Data Protection Law, Berlin), Ute Schenn (Commercial, Stuttgart), Dr. André Schmidt (IT, Data Protection Law, Hamburg).

    The investors Santo Venture Capital and Salvia were represented by honert + partner (Sven Fritsche, Munich).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

  • LUTZ | ABEL ADVISES PRICE F(X) IN EUR 23 MIO EXTENSION OF SERIES B-FINANCING ROUND

    LUTZ | ABEL advises Price f(x) in EUR 23 Mio extension of series B-financing round

    Dr. Bernhard Noreisch, LL.M. Jan-Phillip Kunz, LL.M.
    The start-up Price f(x) managed to score EUR 23 million within the extension of the series B-financing. Leading investors are Digital + Partners and Bain & Company, while Talis Capital increased their investment. LUTZ | ABEL again acted as company counsel of Price f(x) in this transaction.
    recommend
    more
    close

    Founded in 2011, the Munich-based start-up provides a modular SaaS solution for price optimisation management (PO&M) and configure-price-quote (CPQ) for enterprises of any size. The extended investment was let by Digital + Partners, a European B2B technology growth investor and the management consulting firm Bain & Company. Talis Capital, the initial series A investor, followed with a raise, while it brings the series B-financing as a whole to EUR 48 million.
    The new funding allows Price f(x) to further expand their platform capabilities, add new functionality, introduce several new products to the market and place a special focus on sales and marketing in 2020. The start-up expects continued global expansion through organic and partner-enabled growth as well as strategic developments. According to the company, Price f(x) could triple their valuation within the last 12 months.
    LUTZ | ABEL VC experts assisted Price f(x) again in this financing round. Dr. Bernhard Noreisch and Jan-Phillip Kunz provided comprehensive legal advice.

    Consulting lawyers Price f(x) AG
    LUTZ | ABEL Rechtsanwalts PartG mbB (Corporate Law, Venture Capital / M&A)
    Dr. Bernhard Noreisch, LL.M. (Partner)
    Jan-Phillip Kunz, LL.M.